Ezrin expression in the primary hepatocellular carcinoma patients and associated with clinical, pathological characteristics

Pan, Debiao; Wang, Shi; Ye, Hailin; Xu, Shengqian; Ye, Guanxiong

doi:10.4103/0973-1482.200761

Cited by 5 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EZR expression was higher in tumor samples than hepatic tissues and associated with metastasis and differentiation degree [41,42]. High EZR levels have been significantly associated with advanced TNM stage, poor Edmondson's histological grade, macroscopic portal vein invasion, tumor recurrence, and extrahepatic recurrence, and are indepen-dently associated with poor overall survival [43,44].…”

Section: Hepatocellular Carcinomamentioning

confidence: 99%

Perspectives for Targeting Ezrin in Cancer Development and Progression

Silva

Vicari

Machado-Neto

2023

Future Pharmacology

View full text Add to dashboard Cite

Recent advances have been made in understanding molecular markers involved in cancer malignancy, resulting in better tumor staging and identifying new potential therapeutic targets. Ezrin (EZR), a member of the ezrin, radixin, moesin (ERM) protein family, is essential for linking the actin cytoskeleton to the cell membrane and participates in the signal transduction of key signaling pathways such as Rho GTPases and PI3K/AKT/mTOR. Clinical and preclinical studies in a wide variety of solid and hematological tumors indicate that (i) EZR is highly expressed and predicts an unfavorable clinical outcome, and (ii) EZR inhibition reduces proliferation, migration, and invasion in experimental models. The development of pharmacological inhibitors for EZR (or the signaling mediated by it) has opened a new round of investigation, but studies are still limited. The scope of the present review is to survey studies on the expression and clinical impact of EZR in cancer, as well as studies that perform interventions on the function of this gene/protein in cancer cells, providing proof-of-concept of its antineoplastic potential.

show abstract

Section: Hepatocellular Carcinomamentioning

confidence: 99%

Perspectives for Targeting Ezrin in Cancer Development and Progression

Silva

Vicari

Machado-Neto

2023

Future Pharmacology

View full text Add to dashboard Cite

show abstract

Early changes in the urine proteome in a rat liver tumor model

Zhang

Gao

2019

Preprint

View full text Add to dashboard Cite

Urine, as a potential biomarker source among the body fluids, can accumulate many changes in the body due to the lack of a mechanism to maintain a homeostatic state. Previous studies have demonstrated that proteomic technology can find many potential biomarkers to reflect different diseases in the urine.This study aims to detect early changes in the urinary proteome in a rat liver tumor model. The tumor model was established with the Walker-256 carcinosarcoma cell line (W256). Compared to before the injection, ninety-five differential proteins were significantly changed in the experimental rats. At day 3, twelve proteins were identified in the absence of pathological changes, and four of them were altered at all four time-points (B2MG, VCAM1, HA11, and LG3BP). Seven had previously been associated with liver cancer. At day 5, fifty-two differential proteins were identified. At day 7 and day 11, there was a significant decrease in the body weight of the rats, and tumor tissue was observed in the liver. Fifty-two and forty differential proteins were changed significantly at day 7 and day 11, respectively. Of the proteins that were identified at these three time-points, and twenty-four were reported to be associated with liver cancer. Comparing the differential urinary proteins and biological processes of liver tumor model with those in different models of W256 grown in other organs, specific differential protein patterns were found among the four models, which indicates that the differential urinary proteins can reflect the differences when the same tumor cell grown in different organs.Significance: This study demonstrated that (1) the rat liver tumor model caused early changes in urinary proteins may give new insight into the early diagnosis of liver cancer; (2) the same tumor cell grown in different organs can be reflected in differential urinary proteins.All rats were housed under a standard 12-h light/12-h dark cycle, and the room temperature and humidity were maintained at a standard level (22 ± 1 °C, 65-70%). Tumor cell line and CultureWalker 256 tumor cells were cultured in the ascitic fluid of Wistar rats. All cells were harvested from the rats who were given an intraperitoneal injection of 107 Walker 256 carcinoma cells after two cycles of 7 d cell passage. Then, W256 cells were resuspended in phosphate-buffered saline (PBS) before injection. The viability of the cells was detected by the Trypan blue exclusion test using a Neubauer chamber. Rat models of liver cancerA tumor-bearing animal model was established in this study. All Wistar rats were randomly divided into different groups: the control group (n =5), and the Walker-256 (W256) tumor-bearing group (n =12).After anesthesia, the left medial lobe of the liver was exposed. W256 cells (2.5× 10 5 ) were visually injected under the hepatic capsule into this lobe. The injection volume is 0.1 ml. An equal volume of PBS was also injected into the same location of the control rats. Histological analysisIn the W256 model, the livers of the experimental and cont...

show abstract

Ezrin as a prognostic indicator regulates colon adenocarinoma progression through glycolysis

Wang

Yang

Wang

et al. 2020

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim Aerobic glycolysis (the Warburg effect) is a distinctive metabolic hallmark of colon adenocarcinoma. Ezrin was a member of the Ezrin–Radixin–Moesin protein family and has been found profoundly implicated in tumorigenesis. However, the specific functional roles of Ezrin in metabolic reprogramming of colon adenocarcinoma remain poorly characterized and need to be explored. Methods The expression of Ezrin in colon adenocarcinoma tissues was screened by bioinformatics analysis and immunohistochemical assay. Si‐RNA‐mediated transfection and overexpression plasmid transfection were performed in colon adenocarcinoma cells. The proliferation viability was measured using MTT, colony formation, and EdU assays. The migration ability was determined using wound healing and transwell assay. The expression of EMT markers and transcriptional factors was detected using immunofluorescence staining and western blot assays. Glucose uptake, lactate production, and ATP assay were performed to validate the effect of Ezrin on glycolysis‐mediated colon adenocarcinoma progression. Results Ezrin was upregulated in colon adenocarcinoma tissues and associated with poor survival. Ezrin stimulated colon adenocarcinoma cell proliferation, migration, and the process of EMT. Ezrin aroused significant increase in glucose uptake, lactate production, and ATP level in colon adenocarcinoma cells. Further investigations demonstrated that treatment with a glycolytic inhibitor 2‐deoxy‐d‐glucose reversed the effects reduced by Ezrin on colon adenocarcinoma cells. Conclusions Our results evidenced a novel mechanism for colon adenocarcinoma cells proliferation and migration induced by Ezrin via glycolysis.

show abstract

Ezrin expression in the primary hepatocellular carcinoma patients and associated with clinical, pathological characteristics

Abstract: Ezrin protein is highly expressed in human PHC tissue which can be used for the prediction of metastasis disease.

Cited by 5 publications

References 0 publications

Perspectives for Targeting Ezrin in Cancer Development and Progression

Perspectives for Targeting Ezrin in Cancer Development and Progression

Early changes in the urine proteome in a rat liver tumor model

Ezrin as a prognostic indicator regulates colon adenocarinoma progression through glycolysis

Contact Info

Product

Resources

About